Central Pennsylvania Transplant Foundation Incorporated

Organization Overview

Central Pennsylvania Transplant Foundation Incorporated is located in Harrisburg, PA. The organization was established in 2002. According to its NTEE Classification (H90) the organization is classified as: Medical Disciplines Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Central Pennsylvania Transplant Foundation Incorporated is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 12/2021, Central Pennsylvania Transplant Foundation Incorporated generated $150.3k in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 7.9% each year. All expenses for the organization totaled $147.7k during the year ending 12/2021. You can explore the organizations financials more deeply in the financial statements section below.

Mission & Program ActivityExcerpts From the 990 Filing

TAX YEAR

2021

Describe the Organization's Mission:

Part 3 - Line 1

TO PROMOTE AND FOSTER ADVANCES IN TRANSPLANTATION THRU ACTIVITIES THAT HAVE INCLUDED PARTICIPATION IN CLINICAL TRIALS INVESTIGATING DIFFERENT IMMUNOSUPPRESSIVE REGIMENS, DEVELOPMENT OF CLINICAL PATHWAYS TO ENHANCE PATIENT CARE, FORUMS FOR PUBLIC AND PHYSICIAN EDUCATION IN TRANSPLANTA- TION, STUDIES RELATED TO OUTCOMES RESEARCH, LABORATORY WORK IN IMMUNOBIOLOGY AND NEW CONCEPTS IN DIABETES MANAGEMENT.

Describe the Organization's Program Activity:

Part 3 - Line 4a

1. VITAERIS PROTOCOL VKTX01 "A PIVOTAL PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ACTIVE-MEDICATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS". APRIL 2019-PRESENT. 2. USE OF HEPATITIS C POSITIVE DECEASED DONOR KIDNEYS FOR TRANSPLANTATION IN PATIENTS THAT ARE HEPATITIS C NEGATIVE; SEPTEMBER 2019-PRESENT. 3. APOL 1 LONG-TERM KIDNEY TRANSPLANTATION OUTCOMES NETWORK PROTOCOL SUMMARY FOR NON-ENGAGED SITES (APOLLO) NIH SPONSORED. MARCH 2020-PRESENT. 4. ALLOVIR P-150-201 "PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE DOSING INTERVAL, 3-PERIOD STUDY OF THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF ADOPTIVELY TRANSFERRED VIRALYM-M MULTIVIRUS-SPECIFIC T CELLS IN KIDNEY TRANSPLANT RECIPIENTS WITH EITHER HIGH OR LOW LEVELS OF BK VIREMIA. JULY 2020-PRESENT.


DEPRECIATION ON ASSETS USED IN RESEARCH.


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Board, Officers & Key Employees

Name (title)Compensation
Harold C Yang MD
President
$0
Jonathan R Diamond
Director
$0
Mary M Waybill
Physician
$0

Financial Statements

Statement of Revenue
Federated campaigns$0
Membership dues$0
Fundraising events$0
Related organizations$0
Government grants $0
All other contributions, gifts, grants, and similar amounts not included above$0
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$0
Total Program Service Revenue$30,720
Investment income $34
Tax Exempt Bond Proceeds $0
Royalties $0
Net Rental Income $0
Net Gain/Loss on Asset Sales $119,582
Net Income from Fundraising Events $0
Net Income from Gaming Activities $0
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $150,336

Create an account to unlock the data you need.

or